Related Experiment Videos

Apnea of prematurity: theophylline v. caffeine

H Harrison1

  • 1Alaska Neonatology Associates, Providence Hospital, Anchorage 99508.

Alaska Medicine
|October 11, 1992
PubMed

Insights

Theophylline and caffeine citrate effectively treat apnea in preterm infants. Caffeine citrate is particularly effective for persistent apnea unresponsive to theophylline, normalizing pneumocardiograms.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pulmonology
  • Clinical Pharmacology

Background:

  • Preterm infants frequently experience apnea, a potentially serious condition affecting respiratory control.
  • Pneumocardiograms are essential for monitoring cardiorespiratory events in neonates.
  • Apnea and periodic breathing are common challenges in preterm infant care.

Purpose of the Study:

  • To evaluate the efficacy of theophylline and caffeine citrate in managing apnea in preterm infants.
  • To compare the effectiveness of these methylxanthines in normalizing pneumocardiograms.
  • To identify optimal treatment strategies for persistent apnea unresponsive to initial therapy.

Main Methods:

  • Conducted 12-hour pneumocardiograms on 277 preterm infants over 15 months.
  • Defined and measured apnea density and periodic breathing index.
  • Administered theophylline for apnea density >= 5, followed by caffeine citrate for persistent cases.

Main Results:

  • Sixty infants (24%) received theophylline for significant apnea.
  • 16 infants (27% of those on theophylline) required caffeine citrate due to persistent apnea.
  • Caffeine citrate reduced apnea density to 0.8 in 88% of infants, demonstrating high efficacy.

Conclusions:

  • Both theophylline and caffeine citrate are effective in treating apnea in preterm infants.
  • Caffeine citrate is a valuable option for persistent apnea unresponsive to theophylline.
  • Methylxanthine therapy can normalize pneumocardiograms, improving cardiorespiratory stability in neonates.

Related Concept Videos